Evidence map›Paper›PMID 34020328›Full record

ArticleVirology2021

Development of a blocker of the universal phosphatidylserine- and phosphatidylethanolamine-dependent viral entry pathways.

Da-Hoon Song, Gustavo Garcia, Kathy Situ, Bernadette A Chua, Madeline Lauren O Hong, Elyza A Do, Christina M Ramirez, Airi Harui, Vaithilingaraja Arumugaswami, Kouki Morizono

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Da-Hoon SongDivision of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA; UCLA AIDS Institute, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Gustavo GarciaDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, 90095, USA.
Kathy SituDivision of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA; UCLA AIDS Institute, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Bernadette A ChuaDivision of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA; UCLA AIDS Institute, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Madeline Lauren O HongDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA, 90095, USA.
Elyza A DoDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA, 90095, USA.
Christina M RamirezDepartment of Biostatistics, UCLA Fielding School of Public Health, University of California, Los Angeles, CA, 90095, USA.
Airi HaruiDivision of Pulmonary and Critical Care, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
Vaithilingaraja ArumugaswamiDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA, 90095, USA.
Kouki MorizonoDivision of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA; UCLA AIDS Institute, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA. Electronic address: koukimo@ucla.edu.
University of California, Los Angeles · US

Funding

Viral Immunology CoreU19AI149504 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHEN, IRVIN S.Y., KITCHEN, SCOTT G · 2020 to 2024
$14.3M
Metabolic and epigenetic reprogramming of vital organs in SARS-CoV-2 induced systemic toxicityR01DK132735 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARUMUGASWAMI, VAITHILINGARAJA, DEB, ARJUN · 2021 to 2023
$6.0M
Interplay between AMPK and Hippo Signaling Regulates Ocular Antiviral Response to Zika virus infectionR01EY032149 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Vaithilingaraja Arumugaswami, Ashok Kumar · 2021 to 2026
$2.8M
B-cell-specific transduction for anti-HIV antibody and B-cell receptor expressionR01AI145044 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORIZONO, KOKI · 2019 to 2023
$1.9M
The roles of phosphatidylserine and its receptors in HIV replicationR01AI108400 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORIZONO, KOKI · 2013 to 2016
$1.4M
The role of envelope phosphatidylserine in the binding of HIV to target cellsR21AI095004 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORIZONO, KOKI · 2011 to 2012
$424k
NEI NIH HHS R01 EY032149NIAID NIH HHS R01 AI108400NIAID NIH HHS R01 AI145044NIAID NIH HHS R21 AI095004NIAID NIH HHS U19 AI149504NIDDK NIH HHS R01 DK132735
6 · The paper itself

Abstract

Envelope phosphatidylserine (PtdSer) and phosphatidylethanolamine (PtdEtr) have been shown to mediate binding of enveloped viruses. However, commonly used PtdSer binding molecules such as Annexin V cannot block PtdSer-mediated viral infection. Lack of reagents that can conceal envelope PtdSer and PtdEtr and subsequently inhibit infection hinders elucidation of the roles of the envelope phospholipids in viral infection. Here, we developed sTIM1dMLDR801, a reagent capable of blocking PtdSer- and PtdEtr-dependent infection of enveloped viruses. Using sTIM1dMLDR801, we found that envelope PtdSer and/or PtdEtr can support ZIKV infection of not only human but also mosquito cells. In a mouse model for ZIKV infection, sTIM1dMLDR801 reduced ZIKV load in serum and the spleen, indicating envelope PtdSer and/or PtdEtr support in viral infection in vivo. sTIM1dMLDR801 will enable elucidation of the roles of envelope PtdSer and PtdEtr in infection of various virus species, thereby facilitating identification of their receptors and transmission mechanisms.

Indexed as

A549 CellsAnimalsAntiviral AgentsAxl Receptor Tyrosine KinaseCell LineChlorocebus aethiopsCulicidaeFemaleGrowth Arrest-Specific Protein 6HEK293 CellsHumansIntercellular Signaling Peptides and ProteinsMaleMiceMice, Inbred C57BLMice, KnockoutAntiviral AgentsAxl Receptor Tyrosine KinaseGrowth Arrest-Specific Protein 6Ifnar1 protein, mouseIntercellular Signaling Peptides and ProteinsphosphatidylethanolaminePhosphatidylethanolaminesPhosphatidylserinesProto-Oncogene ProteinsReceptor, Interferon alpha-betaReceptor Protein-Tyrosine KinasesAxlCD300ADengue virusEbola virusGas6PhosphatidylethanolaminePhosphatidylserineTIM-1TIM-4Zika virus

Identifiers

PMID34020328
PMCPMC8673400
OpenAlexW3160979935

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.